MacroGenics (MGNX) Stock Forecast, Price Target & Predictions
MGNX Stock Forecast
MacroGenics stock forecast is as follows: an average price target of $10.33 (represents a 179.19% upside from MGNX’s last price of $3.70) and a rating consensus of 'Hold', based on 10 wall street analysts offering a 1-year stock forecast.
MGNX Price Target
The average price target for MacroGenics (MGNX) is $10.33 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $32.00 to $4.00. This represents a potential 179.19% upside from MGNX's last price of $3.70.
MGNX Analyst Ratings
According to 10 Wall Street analysts, MacroGenics's rating consensus is 'Hold'. The analyst rating breakdown for MGNX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (40.00%), 6 'Hold' (60.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
MacroGenics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 07, 2024 | Stephen Willey | Stifel Nicolaus | $6.00 | $3.38 | 77.51% | 62.16% |
| Jul 31, 2024 | Silvan Tuerkcan | JMP Securities | $8.00 | $5.25 | 52.38% | 116.22% |
| Jul 31, 2024 | Mayank Mamtani | B.Riley Financial | $5.00 | $5.25 | -4.76% | 35.14% |
| Jul 29, 2024 | Peter Lawson | Barclays | $9.00 | $5.55 | 62.16% | 143.24% |
| May 23, 2024 | Kaveri Pohlman | BTIG | $9.00 | $4.63 | 94.38% | 143.24% |
| May 13, 2024 | Debjit Chattopadhyay | H.C. Wainwright | $4.00 | $4.38 | -8.75% | 8.11% |
| May 10, 2024 | Peter Lawson | Barclays | $14.00 | $14.67 | -4.57% | 278.38% |
| May 10, 2024 | Etzer Darout | BMO Capital | $8.00 | $14.67 | -45.47% | 116.22% |
| Apr 04, 2024 | Stephen Willey | Stifel Nicolaus | $29.00 | $13.67 | 112.14% | 683.78% |
| Nov 22, 2022 | Charles Zhu | Guggenheim | $12.00 | $6.18 | 94.17% | 224.32% |
The latest MacroGenics stock forecast, released on Aug 07, 2024 by Stephen Willey from Stifel Nicolaus, set a price target of $6.00, which represents a 77.51% increase from the stock price at the time of the forecast ($3.38), and a 62.16% increase from MGNX last price ($3.70).
MacroGenics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 9 |
| Avg Price Target | - | $6.00 | $10.22 |
| Last Closing Price | $3.70 | $3.70 | $3.70 |
| Upside/Downside | -100.00% | 62.16% | 176.22% |
In the current month, the average price target of MacroGenics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to MacroGenics's last price of $3.70. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 18, 2024 | JMP Securities | Market Perform | Market Perform | Hold |
| Sep 18, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Sep 16, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Aug 21, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Aug 15, 2024 | JMP Securities | Market Perform | Market Perform | Hold |
| Jul 31, 2024 | BTIG | Buy | Neutral | Downgrade |
| Jul 31, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Jul 31, 2024 | Guggenheim | Accumulate | Neutral | Downgrade |
| Jul 31, 2024 | B. Riley | - | Neutral | Downgrade |
| Jul 31, 2024 | Guggenheim | Underperform | Accumulate | Downgrade |
MacroGenics's last stock rating was published by JMP Securities on Sep 18, 2024. The company gave MGNX a "Market Perform" rating, the same as its previous rate.
MacroGenics Financial Forecast
MacroGenics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $11.00M | $10.40M | $13.14M | $24.21M | $71.18M | $41.73M | $26.01M | $10.67M | $13.62M | $15.58M | $30.37M | $16.88M | $52.69M | $18.25M | $20.26M | $13.68M | $25.19M | $18.74M | $10.59M | $9.66M | $4.70M | $2.06M |
| Avg Forecast | $8.24M | $36.48M | $8.40M | $8.23M | $27.69M | $87.61M | $20.94M | $14.86M | $32.63M | $50.90M | $29.19M | $96.19M | $64.37M | $29.28M | $14.16M | $23.18M | $22.83M | $34.01M | $32.15M | $26.20M | $26.01M | $14.04M | $10.90M | $9.48M | $13.28M | $15.26M | $14.45M | $18.80M | $3.78M | $1.85M |
| High Forecast | $8.24M | $36.48M | $8.40M | $8.23M | $27.69M | $115.49M | $20.94M | $14.86M | $45.90M | $51.73M | $29.19M | $96.19M | $64.37M | $29.28M | $14.16M | $23.18M | $22.83M | $34.01M | $32.15M | $26.20M | $26.01M | $14.04M | $10.90M | $9.48M | $13.28M | $15.26M | $14.45M | $18.80M | $4.54M | $2.21M |
| Low Forecast | $8.24M | $36.48M | $8.40M | $8.23M | $27.69M | $48.80M | $20.94M | $14.86M | $18.36M | $50.07M | $29.19M | $96.19M | $64.37M | $29.28M | $14.16M | $23.18M | $22.83M | $34.01M | $32.15M | $26.20M | $26.01M | $14.04M | $10.90M | $9.48M | $13.28M | $15.26M | $14.45M | $18.80M | $3.03M | $1.48M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 10 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | 0.34% | 0.20% | 0.45% | 0.25% | 1.11% | 1.43% | 1.84% | 0.46% | 0.60% | 0.46% | 0.94% | 0.64% | 2.03% | 1.30% | 1.86% | 1.44% | 1.90% | 1.23% | 0.73% | 0.51% | 1.24% | 1.11% |
MacroGenics's average Quarter revenue forecast for Mar 24 based on 3 analysts is $14.86M, with a low forecast of $14.86M, and a high forecast of $14.86M. MGNX's average Quarter revenue forecast represents a 35.06% increase compared to the company's last Quarter revenue of $11.00M (Dec 23).
MacroGenics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 10 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | $-151.71M | $-35.50M | $-44.96M | $-37.35M | $15.21M | $-22.11M | $-38.93M | $-63.73M | $-55.07M | $-50.09M | $-37.15M | $-48.54M | $803.00K | $-33.08M | $-43.59M | $-41.91M | $-27.67M | $-41.99M | $-29.19M | $-42.11M | $-48.20M | $-35.68M |
| Avg Forecast | $-7.91M | $-35.01M | $-8.07M | $-7.90M | $-26.58M | $-84.09M | $-20.10M | $-41.33M | $-31.32M | $-48.85M | $-28.02M | $-44.21M | $-57.62M | $-28.11M | $-13.59M | $-47.28M | $-21.91M | $-32.65M | $-30.86M | $-28.01M | $-24.96M | $-13.48M | $-10.47M | $-46.44M | $-12.75M | $-14.65M | $-13.87M | $-35.75M | $-36.59M | $-31.63M |
| High Forecast | $-7.91M | $-35.01M | $-8.07M | $-7.90M | $-26.58M | $-46.84M | $-20.10M | $-33.07M | $-17.62M | $-48.06M | $-28.02M | $-35.36M | $-46.10M | $-28.11M | $-13.59M | $-37.82M | $-21.91M | $-32.65M | $-30.86M | $-22.41M | $-24.96M | $-13.48M | $-10.47M | $-37.15M | $-12.75M | $-14.65M | $-13.87M | $-28.60M | $-29.28M | $-25.30M |
| Low Forecast | $-7.91M | $-35.01M | $-8.07M | $-7.90M | $-26.58M | $-110.85M | $-20.10M | $-49.60M | $-44.06M | $-49.65M | $-28.02M | $-53.05M | $-69.15M | $-28.11M | $-13.59M | $-56.73M | $-21.91M | $-32.65M | $-30.86M | $-33.61M | $-24.96M | $-13.48M | $-10.47M | $-55.72M | $-12.75M | $-14.65M | $-13.87M | $-42.90M | $-43.91M | $-37.96M |
| Surprise % | - | - | - | - | - | - | - | - | 4.84% | 0.73% | 1.60% | 0.84% | -0.26% | 0.79% | 2.86% | 1.35% | 2.51% | 1.53% | 1.20% | 1.73% | -0.03% | 2.45% | 4.16% | 0.90% | 2.17% | 2.87% | 2.10% | 1.18% | 1.32% | 1.13% |
3 analysts predict MGNX's average Quarter EBITDA for Mar 23 to be $-44.21M, with a high of $-35.36M and a low of $-53.05M. This is -390.56% lower than MacroGenics's previous annual EBITDA (Dec 22) of $15.21M.
MacroGenics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 10 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 8 |
| Net Income | - | - | - | - | - | - | - | - | $-45.83M | $17.55M | $57.47M | $-38.25M | $12.80M | $-24.67M | $-40.80M | $-66.25M | $-58.02M | $-52.89M | $-39.94M | $-51.27M | $-2.09M | $-36.04M | $-46.88M | $-44.72M | $-30.40M | $-44.63M | $-31.77M | $-45.02M | $-49.54M | $-37.66M |
| Avg Forecast | $-62.98M | $-41.08M | $-54.79M | $-59.60M | $-39.37M | $13.25M | $-41.41M | $-43.23M | $-9.62M | $-5.97M | $-32.65M | $-46.23M | $-60.71M | $-24.04M | $-61.34M | $-49.45M | $-51.06M | $-44.52M | $-28.54M | $-29.59M | $-45.66M | $-58.32M | $-57.65M | $-49.55M | $-64.02M | $-62.27M | $-60.70M | $-38.21M | $-37.61M | $-33.38M |
| High Forecast | $-62.98M | $-41.08M | $-54.79M | $-59.60M | $-39.37M | $134.20M | $-41.41M | $-34.58M | $-5.55M | $-5.97M | $-32.65M | $-36.99M | $-48.57M | $-24.04M | $-61.34M | $-39.56M | $-51.06M | $-44.52M | $-28.54M | $-23.67M | $-45.66M | $-58.32M | $-57.65M | $-39.64M | $-64.02M | $-62.27M | $-60.70M | $-30.57M | $-30.09M | $-26.71M |
| Low Forecast | $-62.98M | $-41.08M | $-54.79M | $-59.60M | $-39.37M | $-140.83M | $-41.41M | $-51.87M | $-13.69M | $-5.97M | $-32.65M | $-55.48M | $-72.85M | $-24.04M | $-61.34M | $-59.34M | $-51.06M | $-44.52M | $-28.54M | $-35.50M | $-45.66M | $-58.32M | $-57.65M | $-59.46M | $-64.02M | $-62.27M | $-60.70M | $-45.85M | $-45.13M | $-40.06M |
| Surprise % | - | - | - | - | - | - | - | - | 4.77% | -2.94% | -1.76% | 0.83% | -0.21% | 1.03% | 0.67% | 1.34% | 1.14% | 1.19% | 1.40% | 1.73% | 0.05% | 0.62% | 0.81% | 0.90% | 0.47% | 0.72% | 0.52% | 1.18% | 1.32% | 1.13% |
MacroGenics's average Quarter net income forecast for Dec 23 is $-9.62M, with a range of $-13.69M to $-5.55M. MGNX's average Quarter net income forecast represents a -154.79% decrease compared to the company's last Quarter net income of $17.55M (Sep 23).
MacroGenics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 10 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 8 |
| SG&A | - | - | - | - | - | - | - | - | $12.56M | $12.41M | $13.69M | $13.53M | $13.67M | $15.36M | $13.67M | $16.25M | $15.58M | $17.16M | $15.23M | $15.04M | $12.56M | $9.73M | $10.22M | $10.23M | $11.89M | $11.83M | $12.12M | $10.22M | $9.23M | $7.46M |
| Avg Forecast | $5.42M | $24.00M | $5.53M | $5.41M | $18.22M | $57.63M | $13.77M | $10.57M | $21.47M | $33.48M | $19.21M | $11.31M | $16.31M | $19.26M | $9.32M | $12.10M | $15.02M | $22.38M | $21.15M | $8.68M | $17.11M | $9.24M | $7.17M | $6.24M | $8.74M | $10.04M | $9.50M | $8.67M | $2.49M | $1.21M |
| High Forecast | $5.42M | $24.00M | $5.53M | $5.41M | $18.22M | $75.97M | $13.77M | $12.69M | $30.20M | $34.03M | $19.21M | $13.57M | $19.57M | $19.26M | $9.32M | $14.51M | $15.02M | $22.38M | $21.15M | $10.41M | $17.11M | $9.24M | $7.17M | $6.24M | $8.74M | $10.04M | $9.50M | $10.41M | $2.99M | $1.46M |
| Low Forecast | $5.42M | $24.00M | $5.53M | $5.41M | $18.22M | $32.10M | $13.77M | $8.46M | $12.08M | $32.94M | $19.21M | $9.05M | $13.04M | $19.26M | $9.32M | $9.68M | $15.02M | $22.38M | $21.15M | $6.94M | $17.11M | $9.24M | $7.17M | $6.24M | $8.74M | $10.04M | $9.50M | $6.94M | $1.99M | $971.34K |
| Surprise % | - | - | - | - | - | - | - | - | 0.59% | 0.37% | 0.71% | 1.20% | 0.84% | 0.80% | 1.47% | 1.34% | 1.04% | 0.77% | 0.72% | 1.73% | 0.73% | 1.05% | 1.42% | 1.64% | 1.36% | 1.18% | 1.28% | 1.18% | 3.71% | 6.15% |
MacroGenics's average Quarter SG&A projection for Mar 24 is $10.57M, based on 3 Wall Street analysts, with a range of $8.46M to $12.69M. The forecast indicates a -15.81% fall compared to MGNX last annual SG&A of $12.56M (Dec 23).
MacroGenics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 10 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 8 |
| EPS | - | - | - | - | - | - | - | - | $-0.00 | $0.28 | - | $-0.62 | $-1.55 | $-0.40 | $-0.66 | $-1.08 | $-0.95 | $-0.86 | $-0.66 | $-0.90 | $-0.04 | $-0.66 | $-0.94 | $-0.91 | $-0.62 | $-0.91 | $-0.65 | $-0.99 | $-1.34 | $-1.08 |
| Avg Forecast | $-1.00 | $-0.66 | $-0.87 | $-0.95 | $-0.63 | $0.21 | $-0.66 | $-0.64 | $-0.15 | $-0.10 | $-0.52 | $0.45 | $0.10 | $-0.38 | $-0.98 | $-0.85 | $-0.81 | $-0.71 | $-0.46 | $-0.64 | $-0.73 | $-0.93 | $-0.92 | $-1.02 | $-1.02 | $-0.99 | $-0.97 | $-0.75 | $-0.82 | $-0.86 |
| High Forecast | $-1.00 | $-0.66 | $-0.87 | $-0.95 | $-0.63 | $2.14 | $-0.66 | $-0.64 | $-0.09 | $-0.10 | $-0.52 | $0.45 | $0.10 | $-0.38 | $-0.98 | $-0.85 | $-0.81 | $-0.71 | $-0.46 | $-0.64 | $-0.73 | $-0.93 | $-0.92 | $-1.02 | $-1.02 | $-0.99 | $-0.97 | $-0.75 | $-0.66 | $-0.69 |
| Low Forecast | $-1.00 | $-0.66 | $-0.87 | $-0.95 | $-0.63 | $-2.25 | $-0.66 | $-0.64 | $-0.22 | $-0.10 | $-0.52 | $0.45 | $0.10 | $-0.38 | $-0.98 | $-0.85 | $-0.81 | $-0.71 | $-0.46 | $-0.64 | $-0.73 | $-0.93 | $-0.92 | $-1.02 | $-1.02 | $-0.99 | $-0.97 | $-0.75 | $-0.98 | $-1.03 |
| Surprise % | - | - | - | - | - | - | - | - | 0.00% | -2.94% | -0.00% | -1.37% | -15.18% | 1.04% | 0.67% | 1.27% | 1.17% | 1.21% | 1.45% | 1.41% | 0.05% | 0.71% | 1.02% | 0.89% | 0.61% | 0.92% | 0.67% | 1.31% | 1.63% | 1.26% |
According to 6 Wall Street analysts, MacroGenics's projected average Quarter EPS for Dec 23 is $-0.15, with a low estimate of $-0.22 and a high estimate of $-0.09. This represents a -154.81% decrease compared to MGNX previous annual EPS of $0.28 (Sep 23).
MacroGenics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IPSC | Century Therapeutics | $1.26 | $20.00 | 1487.30% | Buy |
| PMVP | PMV Pharmaceuticals | $1.64 | $24.75 | 1409.15% | Buy |
| NGM | NGM Biopharmaceuticals | $1.54 | $16.50 | 971.43% | Buy |
| ANTX | AN2 Therapeutics | $1.08 | $8.75 | 710.19% | Buy |
| NKTX | Nkarta | $3.23 | $21.60 | 568.73% | Buy |
| ZNTL | Zentalis Pharmaceuticals | $3.73 | $21.86 | 486.06% | Buy |
| MOLN | Molecular Partners | $6.06 | $29.00 | 378.55% | Buy |
| PEPG | PepGen | $6.79 | $29.50 | 334.46% | Buy |
| INZY | Inozyme Pharma | $4.42 | $14.67 | 231.90% | Buy |
| MGNX | MacroGenics | $3.70 | $10.33 | 179.19% | Hold |
| DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
| KZR | Kezar Life Sciences | $7.09 | $17.50 | 146.83% | Buy |
| MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
| CCCC | C4 Therapeutics | $6.45 | $13.50 | 109.30% | Buy |
| CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
| SNDX | Syndax Pharmaceuticals | $18.94 | $36.11 | 90.65% | Buy |
| TYRA | Tyra Biosciences | $16.42 | $30.50 | 85.75% | Buy |
| PHVS | Pharvaris | $23.93 | $39.67 | 65.78% | Buy |
| EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
| PTGX | Protagonist Therapeutics | $46.76 | $50.00 | 6.93% | Buy |
MGNX Forecast FAQ
Is MacroGenics a good buy?
No, according to 10 Wall Street analysts, MacroGenics (MGNX) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 40.00% of MGNX's total ratings.
What is MGNX's price target?
MacroGenics (MGNX) average price target is $10.33 with a range of $4 to $32, implying a 179.19% from its last price of $3.7. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will MacroGenics stock go up soon?
According to Wall Street analysts' prediction for MGNX stock, the company can go up by 179.19% (from the last price of $3.7 to the average price target of $10.33), up by 764.86% based on the highest stock price target, and up by 8.11% based on the lowest stock price target.
Can MacroGenics stock reach $6?
MGNX's average twelve months analyst stock price target of $10.33 supports the claim that MacroGenics can reach $6 in the near future.
What are MacroGenics's analysts' financial forecasts?
MacroGenics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $151.1M (high $178.98M, low $112.29M), average EBITDA is $-172M (high $-127M, low $-207M), average net income is $-111M (high $18.84M, low $-273M), average SG&A $100.2M (high $120.65M, low $72.55M), and average EPS is $-1.72 (high $0.21, low $-4.179). MGNX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $61.34M (high $61.34M, low $61.34M), average EBITDA is $-58.878M (high $-58.878M, low $-58.878M), average net income is $-218M (high $-218M, low $-218M), average SG&A $40.35M (high $40.35M, low $40.35M), and average EPS is $-3.486 (high $-3.486, low $-3.486).
Did the MGNX's actual financial results beat the analysts' financial forecasts?
Based on MacroGenics's last annual report (Dec 2023), the company's revenue was $58.75M, which missed the average analysts forecast of $208.91M by -71.88%. Apple's EBITDA was $-168M, beating the average prediction of $-152M by 10.39%. The company's net income was $-9.058M, missing the average estimation of $-94.471M by -90.41%. Apple's SG&A was $52.19M, missing the average forecast of $85.47M by -38.94%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.317 by -99.97%. In terms of the last quarterly report (Dec 2023), MacroGenics's revenue was $11M, missing the average analysts' forecast of $32.63M by -66.28%. The company's EBITDA was $-152M, beating the average prediction of $-31.322M by 384.35%. MacroGenics's net income was $-45.833M, beating the average estimation of $-9.617M by 376.58%. The company's SG&A was $12.56M, missing the average forecast of $21.47M by -41.49%. Lastly, the company's EPS was $-0.0007, missing the average prediction of $-0.153 by -99.54%